(Total Views: 628)
Posted On: 02/03/2021 7:20:55 PM
Post# of 148903
Re: KenChowder #76086
And this could only be the beginning. Imagine a small company having Covid and HIV on its resume. They will undoubtedly then have no trouble in getting other trials quickly subscribed. Ohm's list is 65, however lets go with 30. If they get positive results with even say 2 ailments, it wont be they failed with 28, it will be they doubled the number of ailments they can treat, and a whole lot of folks will get to enjoy longer happy lives..
So the next step in their evolution, is which ones to tackle next, and how many do they tackle at once, after all you do want to add to that resume.
Right now they are recruiting - Long Haulers (soon), NASH, mTNBC & Solid Tumors, plus looking to get mono therapy for HIV. I think that should be enough for 2021.
One of my concerns is -
MM no.
SC yes.
LH no, because the FDA does not want one small company to corner the market for Covid treatment.
Currently, the Long Haulers study shows Outcome Measures as https://clinicaltrials.gov/ct2/show/NCT046788...amp;rank=3
Primrary at 28 days, and all Secondary at 56 days.
So the next step in their evolution, is which ones to tackle next, and how many do they tackle at once, after all you do want to add to that resume.
Right now they are recruiting - Long Haulers (soon), NASH, mTNBC & Solid Tumors, plus looking to get mono therapy for HIV. I think that should be enough for 2021.
One of my concerns is -
MM no.
SC yes.
LH no, because the FDA does not want one small company to corner the market for Covid treatment.
Currently, the Long Haulers study shows Outcome Measures as https://clinicaltrials.gov/ct2/show/NCT046788...amp;rank=3
Primrary at 28 days, and all Secondary at 56 days.
(1)
(0)Scroll down for more posts ▼
